Calithera Biosciences, Inc. Watch

from 10-Q 6 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Amendment to the Asset Purchase Agreement

from 10-Q 75 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Asset Purchase Agreement Between Millennium Pharmaceuticals, Inc. and Calithera Biosciences, Inc. Dated as of October 18, 2021

from 10-Q 14 pages Calithera Biosciences, Inc. Amended and Restated Severance Benefit Plan Approved by the Compensation Committee of the Board of Directors: August 28, 2017 Amended and Restated by the Compensation Committee of the Board of Directors: August 21, 2021

from 8-K 31 pages Preferred Stock Purchase Agreement

from 10-Q 6 pages Fourth Amendment to Lease Agreement

from 10-Q 8 pages Calithera Biosciences, Inc. Restricted Stock Unit Grant Notice

from 10-Q 14 pages Calithera Biosciences, Inc. Severance Benefit Plan Approved by the Compensation Committee of the Board of Directors: August 28, 2017

from 10-Q 4 pages Third Amendment to Lease Agreement

from 10-Q 107 pages Collaboration and License Agreement by and Between Incyte Corporation and Calithera Biosciences, Inc. Dated as of January 27, 2017

from 10-K 6 pages A. Pay You Cash Severance in the Form of Continuing Payments, Subject to Payroll Withholdings and Applicable Deductions and Payable in Accordance With the Company’s Regular Payroll Schedule, of Your Base Salary in Effect as of the Separation From Service (The “Severance Payments”) for a Period of Six (6) Months Following Your Separation From Service Date; Provided, However, That No Payments Will Be Made Prior to the 60th Day Following Your Separation From Service Date, and on That 60th Date, the Company Will Pay You a Lump Sum Payment Equal to the Payments That Would Have Been Paid Earlier but for the Delay Due to This Paragraph, With the Balance Paid Thereafter as Originally Scheduled; B. Pay You Cash Severance in an Amount Equal to a Prorated Amount of Your Target Management Bonus for the Year in Which Your Employment

from 10-K 6 pages A. Pay You Cash Severance in the Form of Continuing Payments, Subject to Payroll Withholdings and Applicable Deductions and Payable in Accordance With the Company’s Regular Payroll Schedule, of Your Base Salary in Effect as of the Separation From Service (The “Severance Payments”) for a Period of Six (6) Months Following Your Separation From Service Date; Provided, However, That No Payments Will Be Made Prior to the 60th Day Following Your Separation From Service Date, and on That 60th Date, the Company Will Pay You a Lump Sum Payment Equal to the Payments That Would Have Been Paid Earlier but for the Delay Due to This Paragraph, With the Balance Paid Thereafter as Originally Scheduled; B. Pay You Cash Severance in an Amount Equal to a Prorated Amount of Your Target Management Bonus for the Year in Which Your Employment

from 10-K 7 pages Re:separation Agreement Dear Will: This Letter Sets Forth the Substance of the Separation Agreement (The “Agreement”) That Calithera Biosciences, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1.separation Date. Your Last Day of Work With the Company and Your Employment Termination Date Will Be December 31, 2016 (The “Separation Date”). 2.final Pay. on the Separation Date, the Company Will Pay You All Accrued Salary, and All Accrued and Unused Vacation Earned Through the Separation Date, Subject to Standard Payroll Deductions and Withholdings. You Are Entitled to These Payments Regardless of Whether or Not You Sign This Agreement

from 8-K 38 pages Stock Purchase Agreement by and Between Incyte Corporation and Calithera Biosciences, Inc. Dated as of January 27, 2017 Calithera Biosciences, Inc. Stock Purchase Agreement

from 10-Q 10 pages April 21, 2016 Keith Orford C/O Calithera Biosciences, Inc. 343 Oyster Point Boulevard, Suite 200 South San Francisco, Ca 94080 Re: Amended and Restated Offer Letter Dear Keith

from 10-Q 11 pages Second Amendment to Lease Agreement

from 10-Q 47 pages License and Research Agreement by and Between Calithera Biosciences Inc. and High Point Pharmaceuticals, LLC Transtech Pharma LLC Dated as of March 5, 2015

from 10-K 25 pages Collaboration and License Agreement

from S-1/A 10 pages Calithera Biosciences, Inc. 2014 Employee Stock Purchase Plan Adopted by the Board of Directors: September 18, 2014 Approved by the Stockholders: September 19, 2014

from S-1/A 13 pages Calithera Biosciences, Inc. Stock Option Grant Notice

from S-1/A 24 pages Calithera Biosciences, Inc. 2014 Equity Incentive Plan Adopted by the Board of Directors: September 18, 2014 Approved by the Stockholders: September 19, 2014 Ipo Date: , 2014